Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: Wright Reports
Provider: GlobalData
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

BioPorto A/S Reaffirms FY 2013 Guidance

Tuesday, 7 May 2013 03:45am EDT 

BioPorto A/S expects fiscal 2013 revenues to be on a par with fiscal 2012 and a loss in fiscal 2013, and this is expected to be slightly greater than in fiscal 2012 due to the initiation of clinical trials. The Company reported fiscal 2012 revenue of DKK17.9 million and net loss of DKK13.9 million. 

Related Company News

Company Quote

-0.02 -1.15%
10:59am EST